GlaxoSmithKline plc (GSK) Earns “Buy” Rating from Citigroup Inc.
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reiterated by analysts at Citigroup Inc. in a research report issued on Friday.
A number of other research analysts also recently weighed in on the company. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a report on Wednesday, July 27th. JPMorgan Chase & Co. upped their price target on GlaxoSmithKline plc from GBX 1,470 ($19.19) to GBX 1,800 ($23.50) and gave the stock a “neutral” rating in a research note on Tuesday, July 12th. BNP Paribas restated a “neutral” rating and issued a GBX 1,430 ($18.67) price target on shares of GlaxoSmithKline plc in a research note on Sunday, July 3rd. Goldman Sachs Group Inc. restated a “buy” rating and issued a GBX 1,800 ($23.50) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, July 12th. Finally, Morgan Stanley upped their price target on GlaxoSmithKline plc from GBX 1,500 ($19.58) to GBX 1,650 ($21.54) and gave the stock an “equal weight” rating in a research note on Monday, July 11th. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 1,676.44 ($21.88).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1653.00 on Friday. The company’s market capitalization is GBX 80.35 billion. GlaxoSmithKline plc has a one year low of GBX 1,227.50 and a one year high of GBX 1,716.50. The company’s 50-day moving average price is GBX 1,652.33 and its 200-day moving average price is GBX 1,532.89.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/24/glaxosmithkline-plc-gsk-earns-buy-rating-from-citigroup-inc-2.html
The company also recently disclosed a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Thursday, August 11th will be given a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 11th. This represents a dividend yield of 1.12%.
In related news, insider Cartwright,Stacey purchased 461 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The stock was bought at an average price of GBX 1,559 ($20.35) per share, for a total transaction of £7,186.99 ($9,381.27). Also, insider Witty,Sir Andrew P sold 10,000 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlaxoSmithKline plc and related companies with MarketBeat.com’s FREE daily email newsletter.